Prioritizing Genomic Applications for Action by Level of Evidence: A Horizon-Scanning Method

2013/11/14 by W D Dotson, W. David Dotson, M P Douglas +27 · 25 citations
Biochemistry, Genetics and Molecular Biology · Pharmacology, Toxicology and Pharmaceutics · Mathematics · #Biomedical Text Mining and Ontologies #Pharmacogenetics and Drug Metabolism #Statistical Methods in Clinical Trials

paper · doi:10.1038/clpt.2013.226

Abstract

As evidence accumulates on the use of genomic tests and other health-related applications of genomic technologies, decision makers may increasingly seek support in identifying which applications have sufficiently robust evidence to suggest they might be considered for action. As an interim working process to provide such support, we developed a horizon-scanning method that assigns genomic applications to tiers defined by availability of synthesized evidence. We illustrate an application of the method to pharmacogenomics tests.

Citations

• CPIC: Clinical Pharmacogenetics Implementation Consortium of the Pharmacogenomics Research Network
• Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C19 Genotype and Clopidogrel Therapy: 2013 Update
• Pharmacogenomics Knowledge for Personalized Medicine

Cited by

• Challenges of coverage policy development for next-generation tumor sequencing panels: experts and payers weigh in. [europepmc]
• A public health perspective on a national precision medicine cohort: balancing long-term knowledge generation with early health benefit. [europepmc]
• Genomics in Public Health: Perspective from the Office of Public Health Genomics at the Centers for Disease Control and Prevention (CDC). [europepmc]
• What is translational genomics? An expanded research agenda for improving individual and population health. [europepmc]
• A knowledge base for tracking the impact of genomics on population health. [europepmc]
• Precision Medicine at the University of Alabama at Birmingham: Laying the Foundational Processes Through Implementation of Genotype-Guided Antiplatelet Therapy. [europepmc]
• Precisely Where Are We Going? Charting the New Terrain of Precision Prevention. [europepmc]
• From public health genomics to precision public health: a 20-year journey. [europepmc]
• Which Lynch syndrome screening programs could be implemented in the "real world"? A systematic review of economic evaluations. [europepmc]
• Insurance Coverage Policies for Pharmacogenomic and Multi-Gene Testing for Cancer. [europepmc]
• Pharmacogenetic testing in the Veterans Health Administration (VHA): policy recommendations from the VHA Clinical Pharmacogenetics Subcommittee. [europepmc]
• Evaluating the role of public health in implementation of genomics-related recommendations: a case study of hereditary cancers using the CDC Science Impact Framework. [europepmc]
• A collaborative translational research framework for evaluating and implementing the appropriate use of human genome sequencing to improve health. [europepmc]
• Ten years of Genome Medicine. [europepmc]
• Effects of Genetic Variants Associated with Familial Hypercholesterolemia on Low-Density Lipoprotein-Cholesterol Levels and Cardiovascular Outcomes in the Million Veteran Program. [europepmc]
• The Genetic Education for Men (GEM) Trial: Development of Web-Based Education for Untested Men in BRCA1/2-Positive Families. [europepmc]
• Effective Identification of Lynch Syndrome in Gastroenterology Practice. [europepmc]
• Use of Real-World Evidence in US Payer Coverage Decision-Making for Next-Generation Sequencing-Based Tests: Challenges, Opportunities, and Potential Solutions. [europepmc]
• A scoping review of social and behavioral science research to translate genomic discoveries into population health impact. [europepmc]
• Strategic vision for improving human health at The Forefront of Genomics. [europepmc]
• From genes to public health: are we ready for DNA-based population screening? [europepmc]
• Swiss cost-effectiveness analysis of universal screening for Lynch syndrome of patients with colorectal cancer followed by cascade genetic testing of relatives. [europepmc]
• Health equity in the implementation of genomics and precision medicine: A public health imperative. [europepmc]
• Nurses' Knowledge, Attitudes, Confidence, and Practices with Genetics and Genomics: A Theory-Informed Integrative Review Protocol. [europepmc]
• Population Genomic Screening for Three Common Hereditary Conditions : A Cost-Effectiveness Analysis. [europepmc]

Related

• Diagnostic yield and clinical utility of whole exome sequencing using an automated variant prioritization system, EVIDENCE
• A Standardized Measurement and Valuation Scale of Genomic Utility for Policy Decisions: The GUV Scale
• Pharmacogenomics in the Age of GWAS, Omics Atlases, and PheWAS
• Smaller p-values in genomics studies using distilled historical information
• Developing AI algorithms to analyse genomic data for disease diagnosis, personalised medicine and genome editing